These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12540801)

  • 41. Complete regression of hepatocellular carcinoma under tamoxifen.
    Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C
    Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095
    [No Abstract]   [Full Text] [Related]  

  • 42. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Complete remission of hepatocarcinoma metastasis during palliative treatment with tamoxifen].
    Morra A; Sponza M; Stanta G; Urban F; Frezza M
    Radiol Med; 1998 Sep; 96(3):263-5. PubMed ID: 9850724
    [No Abstract]   [Full Text] [Related]  

  • 44. Octreotide: no benefit in advanced liver cancer.
    Tilstone C
    Lancet Oncol; 2007 Feb; 8(2):103. PubMed ID: 17288044
    [No Abstract]   [Full Text] [Related]  

  • 45. Tamoxifen treatment in hepatocellular carcinoma.
    Farinati F
    Gastroenterology; 1996 Jul; 111(1):272-4. PubMed ID: 8698220
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
    Lersch C; Schmelz R; Erdmann J; Hollweck R; Schulte-Frohlinde E; Eckel F; Nader M; Schusdziarra V
    Hepatogastroenterology; 2004; 51(58):1099-103. PubMed ID: 15239254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Octreotide for cancer of the liver and biliary tree.
    Kouroumalis EA
    Chemotherapy; 2001; 47 Suppl 2():150-61. PubMed ID: 11275708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.
    Liu HL; Huo L; Wang L
    Acta Pharmacol Sin; 2004 Oct; 25(10):1380-6. PubMed ID: 15456543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is octreotide useful for hepatic metastases due to non-neuroendocrine primary tumors?
    Kiki PG; Nikos E; Ioannis S; Vassilis K
    Clin Oncol (R Coll Radiol); 2002 Aug; 14(4):330-1. PubMed ID: 12206649
    [No Abstract]   [Full Text] [Related]  

  • 50. [Tamoxifen and hepatocarcinoma].
    Mondragón Sánchez R
    Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo.
    Jia WD; Xu GL; Sun HC; Wang L; Xu RN; Xue Q
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):404-9. PubMed ID: 14599948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
    Filosso PL; Ruffini E; Oliaro A; Rena O; Casadio C; Mancuso M; Turello D; Cristofori RC; Maggi G
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):819-24. PubMed ID: 15821649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
    Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
    Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variant liver estrogen and response to tamoxifen.
    Villa E; Camellini L; Dugani A; Buttafoco P; Grottola A; Manenti F
    Gastroenterology; 1996 Jul; 111(1):271-2. PubMed ID: 8698219
    [No Abstract]   [Full Text] [Related]  

  • 57. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.
    Reynaert H; Colle I
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of metastatic carcinoid tumours with octreotide.
    Ozbey N
    Int J Clin Pract; 2002 Jun; 56(5):407. PubMed ID: 12137455
    [No Abstract]   [Full Text] [Related]  

  • 60. Relationship between octreotide and breast surgery.
    Carcoforo P; Soliani G; Maestroni U; Maravedgias K; Sortini D; Avital I
    Breast J; 2005; 11(3):223. PubMed ID: 15871716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.